Management of Hypertension in Patients with Chronic Kidney Disease and Diabetes Mellitus

American Journal of Medicine

Volumn 121, Issue 8 SUPPL. 1, 2008, Pages

  Palmer, Biff F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Blood pressure; High cardiovascular risk; Hypertension; Renoprotection

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRBESARTAN; LOSARTAN; PLACEBO; PRAVASTATIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; TRIACYLGLYCEROL; VALSARTAN; VERAPAMIL;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL DIABETES; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 47149101627     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.018     Document Type: Article

References (41)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S266
2. Rosamond W., Flegal K., Friday G., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommitte. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
3. Parikh N.I., Hwang S.J., Larson M.G., Meigs J.B., Levy D., and Fox C.S. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 166 (2006) 1884-1891
4. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
5. Saydah S., Eberhardt M., Rios-Burrows N., Williams D., Geiss L., and Dorsey R. Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 56 (2007) 161-165
6. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. http://www.usrds.org/adr.htm Accessed October 15, 2007
7. Hsu C.Y., Vittinghoff E., Lin F., and Shlipak M.G. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141 (2004) 95-101
8. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161 (2001) 1207-1216
9. Smith D.H., Gullion C.M., Nichols G., Keith D.S., and Brown J.B. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 15 (2004) 1300-1306
10. Mainous III A.G., Baker R., Koopman R.J., et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia 50 (2007) 934-940
11. Movahed M.R., Hashemzadeh M., and Mazen Jamal M.M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105 (2005) 315-318
12. Booth G.L., Kapral M.K., Fung K., and Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368 (2006) 29-36
13. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
14. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 11 (1993) 319-325
15. Zhang Y., Lee E.T., Devereux R.B., et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 47 (2006) 410-414
16. Schmieder R.E., Hilgers K.F., Schlaich M.P., and Schmidt B.M.W. Renin-angiotensin system and cardiovascular risk. Lancet 369 (2007) 1208-1219
17. Griffin K.A., and Bidani A.K. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 1 (2006) 1054-1065
18. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
19. Bosch J., Lonn E., Pogue J., Arnold J.M., Dagenais G.R., Yusuf S., and HOPE/HOPE-TOO Study investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112 (2005) 1339-1346
20. Bosch J., Yusuf S., Gerstein H.C., et al., DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
21. Dahlof B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
22. Julius S., Kjeldsen S.E., Weber M., et al., VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
23. Julius S., Weber M.A., Kjeldsen S.E., et al. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 48 (2006) 385-391
24. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: network meta-analysis. [published correction appears in Lancet. 2007;369:1518]. Lancet 369 (2007) 201-207
25. Ruggenenti P., Fassi A., Ilieva A.P., et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
26. Ruggenenti P., Perna A., Ganeva M., Ene-lordache B., Remuzzi G., and BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 17 (2006) 3472-3481
27. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Amer P., and Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
28. Brenner B.M., Cooper M.E., de Zeeuw D., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
29. Bakris G.L., Weir M.R., Shanifar S., et al., RENAAL Study Investigators. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 163 (2003) 1555-1565
30. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
31. Barnett A.H., Bain S.C., Bouter P., et al., Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004) 1952-1961
32. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blockers and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 361 (2003) 117-124
33. Kunz R., Friedrich C., Wolbers M., and Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
34. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
35. ONTARGET: Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial and TRANSCEND: Telmisartan Randomized Assessment Study in Ace-intolerant Subjects With Cardiovascular Disease Trial. [ClinicalTrials.gov Web site]. http://www.clinicaltrials.gov/ct/show/NCT00153101?order=1 Accessed July 31, 2007
36. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
37. Julius S., Nesbitt S.D., Egan B.M., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697
38. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 157 (1997) 657-667
39. Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
40. Hillege H.L., Fidler V., Diercks G.F., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
41. Cushman W.C., Grimm Jr. R.H., Cutler J.A., et al., ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 12A (2007) 44i-55i